A couple may go to trial against Merck, Sharp, & Dohme Corp. on claims that the osteoporosis drug Fosamax caused the wife’s femur fracture, a federal trial court in New Jersey held April 11 (Glynn v. Merck Sharp & Dohme Corp. (In re Fosamax (Alendronate Sodium) Products Liability Litigation, D.N.J., 3:08-cv-00008-GEB-LHG, 4/11/13).
The U.S. District Court for the District of New Jersey partially denied summary judgment to Merck, finding fact questions concerning whether a different warning would have caused plaintiff Bernadette Glynn’s physicians to prescribe the drug for her in a different manner.
Bernadette and Richard Glynn’s ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.